Abstract: Methods of reducing the viability of cancer cells, preventing cancer cells of a subject from developing resistance to TTFields, and restoring sensitivity of cancer cells to TTFields by recommending or prescribing a PTGER3 inhibitor to a subject and applying an alternating electric field to the cancer cells are provided. In some instances, sensitivity of cancer cells to TTFields can be restored with one or more PTGER3 inhibitors (e.g., NSAIDs, cox2 inhibitors).

Abstract: The invention provides compositions comprising a ribonucleotide or ribonucleotides or a deoxyribonucleotide or deoxyribonucleotides encoding at least two cell fate determinants (CFD) selected from the group consisting of PBX2, ACTN2, POU2F1, HAND1, TRIM24, GATA4, PBX1, ZBTB39, HAND2, IKZF4, NROB2, NACA2, SMYD1, JUP, NEUROD1, CKMT2, TSHZ2, MITF, MYOCD, and PPARGC1B. The compositions are useful in the treatment of cardiac disorders and in reprogramming a mesenchymal stem cell (MSC) to an autologous induced cardiomyocyte (iCM).

Abstract: Provided methods of inhibiting a glioblastoma stem-like cell (GSC), methods of treating a subject with glioblastoma, and methods of reprogramming an astrocyte to a glioblastoma stem-like cell (GSC).

Abstract: Provided herein are methods of assessing, detecting, monitoring the presence, or monitoring progression of cancer in a subject, or assessing or predicting prognosis or survival of a subject having cancer. Also provided are methods of measuring chromosomal accessibility of the chromosomal locus of cancer master regulator genes or downstream genes in the master regulator network, methods of measuring chromosomal DNA methylation at the chromosomal locus of cancer master regulator genes or downstream genes, and methods measuring chromosomal DNA methylation at the chromosomal locus of the promoter and/or regulatory regions of cancer master regulator genes or downstream genes.

Abstract: Provided herein are methods of assessing, detecting, monitoring the presence, or monitoring progression of cancer in a subject, or assessing or predicting prognosis or survival of a subject having cancer. Also provided are methods of treating cancer based on an increase in the expression of one or more top master regulators of a cancer.

Abstract: Methods of reducing the viability of cancer cells, preventing cancer cells of a subject from developing resistance to TTFields, and restoring sensitivity of cancer cells to TTFields by recommending or prescribing a PTGER3 inhibitor to a subject and applying an alternating electric field to the cancer cells are provided. In some instances, sensitivity of cancer cells to TTFields can be restored with one or more PTGER3 inhibitors (e.g., NSAIDs, cox2 inhibitors).

Abstract: Example embodiments of the present invention address problems in computational biology and network theory. As mentioned above, example embodiments enable the determination of where to set a threshold cutoff level to maximize sensitivity of a gene expression profile while minimizing the false discovery rate (FDR). Some example embodiments exploit the filtered gene expression profile to discover potential master regulators that may be targetable by various perturbagen-based treatments. Other example embodiments facilitate the harvesting of meaningful data from other type of network and node statistics inputs, even those not related specifically to computational biology or the exploitation of inferred gene expression profiles.